SMi's 7th annual Orphan Drugs and Rare Diseases UK Conference

Orphan Drugs UK 2017: Discussing strategies for patient engagement, market access and gene therapies to enhance rare disease and orphan drug research

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th and 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.

Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing. 

Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.

Featured Speakers:

.    Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals

.    Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital

.    Oliver Timmis, CEO, AKU Society

.    Stuart Hughes, Director, Head of Pharmacology, Vertex

.    Christine Lavery, Group Chief Executive, MPS Society

.    Olaf Ritzeler, External Innovation Lead, Sanofi

.    Stephen Marcus, CEO, Cantex Pharmaceuticals

Exclusive highlights in 2017:

.    Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes

.    Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children

.    Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement

Speakers: ADB Medical, Chiesi Farmaceutici S.p.A., Sanofi, Summit Therapeutics, Findacure, AKU Society, GlaxoSmithKline, Vertex Pharmaceuticals, MPS Society, Birmingham Children's Hospital, Deutsches Krebsforschungszentrum, Alexion Pharma GmbH, Cantex Pharmaceuticals, Actelion Pharmaceuticals, Action Duchenne, Selecta Biosciences, Cambridge Rare Disease Network (CRDN), Birmingham Children's Hospital

Time: 8:00 am to 5:30 pm